ATC Group: C01AA Digitalis glycosides

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of C01AA in the ATC hierarchy

Level Code Title
1 C Cardiovascular system
2 C01 Cardiac therapy
3 C01A Cardiac glycosides
4 C01AA Digitalis glycosides

Group C01AA contents

Code Title
C01AA01 Acetyldigitoxin
C01AA02 Acetyldigoxin
C01AA03 Digitalis leaves
C01AA04 Digitoxin
C01AA05 Digoxin
C01AA06 Lanatoside C
C01AA07 Deslanoside
C01AA08 Metildigoxin
C01AA09 Gitoformate
C01AA52 Acetyldigoxin, combinations

Active ingredients in C01AA

Active Ingredient Description
Deslanoside
Digoxin

Digoxin increases contractility of the myocardium by direct activity. The primary action of digoxin is specifically to inhibit adenosine triphosphatase, and thus sodium-potassium (Na+ - K+) exchange activity, the altered ionic distribution across the membrane resulting in an augmented calcium ion influx and thus an increase in the availability of calcium at the time of excitation-contraction coupling. The potency of digoxin may therefore appear considerably enhanced when the extracellular potassium concentration is low, with hyperkalaemia having the opposite effect.

Lanatoside C
Metildigoxin

Metildigoxin, a methyl derivative of digoxin, is a cardiac glycoside a type of drug that can be used in the treatment of congestive heart failure and cardiac arrhythmia.

Related product monographs

Title Information Source Document Type  
DIGOXIN Solution for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
DIGOXIN Tablets Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
Lanoxin 125 Tablets Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
LANOXIN Solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR
LANOXIN Tablet FDA, National Drug Code (US) MPI, US: SPL/PLR